We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo
WHX Labs Dubai 2026
Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Schizophrenia Drug Kills Tuberculosis Bacteria

By Biotechdaily staff writers
Posted on 23 Mar 2005
Researchers have found that phenothiazine, a drug used to treat schizophrenia, kills the bacteria that cause tuberculosis (TB) through the inhibition of the bacterial enzyme type II NADH dehydrogenase.

In 1993 the World Health Organization declared TB a global health emergency; approximately one third of the world's population is infected, and an estimated three million die from the disease each year. Especially alarming has been the spread of drug-resistant strains of TB. By the late 1990s, scientific experts and international health officials warned that drug-resistant strains were spreading faster than had been anticipated. Some believe that unless major new treatment strategies are initiated in source countries, drug-resistant TB will eventually become epidemic even in areas with good control programs, such as Europe and the United States.

In the current study, investigators at the University of Pennsylvania School of Medicine (Philadelphia, USA) used the anti-schizophrenia drug phenothiazine to treat Mycobacterium tuberculosis bacteria growing in culture and to treat mice that had been infected with the bacteria. They reported in the March 14, 2005, online edition of the Proceedings of the [U.S.] National Academy of Sciences that several phenothiazine analogs were potent killers of tuberculosis bacteria in culture and suppressed bacterial growth in a mouse model of acute infection. The target of the drug was found to be the enzyme type II NADH dehydrogenase.

"What we have now is a new target in TB,” said senior author Dr. Harvey Rubin, professor of medicine at the University of Pennsylvania School of Medicine. "We have been able to find at least the beginnings of a class of compounds that we can start working with and that we know is biochemically active against the TB bacteria in culture and in small animals. We discovered that if you inhibit the very first enzyme in the chain, you inhibit everything else downstream and eventually the bacteria die.”



Related Links:
University of Pennsylvania School of Medicine

Gold Member
Hematology Analyzer
Medonic M32B
POC Helicobacter Pylori Test Kit
Hepy Urease Test
CBM Analyzer
Complete Blood Morphology (CBM) Analyzer
HBV DNA Test
GENERIC HBV VIRAL LOAD VER 2.0

Latest BioResearch News

Genome Analysis Predicts Likelihood of Neurodisability in Oxygen-Deprived Newborns
23 Mar 2005  |   BioResearch

Gene Panel Predicts Disease Progession for Patients with B-cell Lymphoma
23 Mar 2005  |   BioResearch

New Method Simplifies Preparation of Tumor Genomic DNA Libraries
23 Mar 2005  |   BioResearch